Last update March 29, 2022
Very Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Norethisterone is also known as
Norethisterone in other languages or writings:
Norethisterone belongs to this group or family:
Main tradenames from several countries containing Norethisterone in its composition:
|Tmax||1 - 2||hours|
|T½||8 - 10||hours|
|Theoretical Dose||0.0001 - 0.0004||mg/Kg/d|
|Relative Dose||0.7 - 1.9||%|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Norethisterone or Nornorethindrone is a contraceptive progestogen derived from 19-northstastterone used as a single product or associated with ethinylestradiol. Oral administration daily or in intramuscular injection every 8 weeks.
It is excreted in breast milk in clinically significant amount (Betrabet 1987, Toddywalla 1980, Saxena 1977) and no problems have been observed in infants whose mothers took it. (WHO 1994, Shaaban 1991, Giner 1976, Karim 1971)
Plasma levels of these infants were undetectable or very low.(Betrabet 1987)
No alterations have been observed in the amount or composition of breast milk in mothers treated with norethindrone. (Giner 1976)
WHO List of Essential Medicines 2002: rates it as compatible with breastfeeding after the 6th postnatal week. (WHO/OMS 2002)
During breastfeeding progestin-only contraceptives are preferable to those combined with estrogen and, in this case, those with a lower dose of estrogen. (CDC 2016, WHO/OMS 2015, Altshuler 2015, Berens 2015, CLM 2012, Moretti 2000)
For the first 4-6 weeks postpartum, non-hormonal methods are the first choice, followed by IUDs and progestogen implants. (Berens 2015, Mwalwanda 2013, Rowe 2013, CLM 2012)
See below the information of these related products: